Stock Price Quote

ORCHID PHARMA LTD.

NSE : ORCHPHARMABSE : 524372ISIN CODE : INE191A01027Industry : Pharmaceuticals & DrugsHouse : Private
BSE1062.7014 (+1.33 %)
PREV CLOSE ( ) 1048.70
OPEN PRICE ( ) 1055.00
BID PRICE (QTY) 1062.65 (14)
OFFER PRICE (QTY) 1064.85 (2)
VOLUME 3099
TODAY'S LOW / HIGH ( )1055.00 1085.00
52 WK LOW / HIGH ( )414 1358.8
NSE1064.2515.55 (+1.48 %)
PREV CLOSE( ) 1048.70
OPEN PRICE ( ) 1080.00
BID PRICE (QTY) 1064.25 (2)
OFFER PRICE (QTY) 1064.95 (1)
VOLUME 15003
TODAY'S LOW / HIGH( ) 1062.65 1090.00
52 WK LOW / HIGH ( )411.55 1359.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 01-07 1992
Management Info
Ram Gopal Agarwal - Chairman Manish Dhanuka - Managing Director
Registered Office

Address Orchid Towers,313 , Valluvar Kottam High Road,Nungambakkam,
Chennai,
Tamil Nadu-600034

Phone 044-28211000

Email corporate@orchidpharma.com / nikitak@orchidpharma.com

Website www.orchidpharma.com

Registrars Details
Abhipra Capital Ltd
Abhipra Complex,A-387 Azadpur,Dilkush Indl.Area G T Karnal Road ,New Delhi
Listing : BSE, NSE

NEWS

06Jun Orchid Pharma gets DCGI’s approval for
Orchid Pharma has received Drugs Controller General of India (DCGI) appr..
06Jun Orchid Pharma jumps on getting DCGI’s
Orchid Pharma is currently trading at Rs. 1040.85, up by 42.50 points or..
04Jun Orchid Pharma informs about investor r
Pursuant to Regulation 30 read with Schedule III of Securities and Excha..
17May Orchid Pharma informs about analyst meet
Orchid Pharma has informed that an Analysts/Investors Earning Call hoste..
08Feb Orchid Pharma informs about outcome of
Orchid Pharma has informed that pursuant to Regulation 30 read Schedule..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit331.87947.49
Gross Profit 299.61 915.23
Operating Profit 418.11410.7
Net Sales 2171.028193.68

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE)
peergroup  6838.70 (5.00%)
M.Cap ( in Cr)15749.95
Astrazeneca Pharma I (BSE)
peergroup  6520.50 (2.67%)
M.Cap ( in Cr)15943.50
NGL Fine-Chem (BSE)
peergroup  2391.80 (2.42%)
M.Cap ( in Cr)1491.99
Strides Pharma Scien (BSE)
peergroup  989.40 (5.02%)
M.Cap ( in Cr)8954.53
Natco Pharma (BSE)
peergroup  1222.40 (3.99%)
M.Cap ( in Cr)21271.98

Shareholding Pattern

PROMOTERS 69.84%
MUTUAL FUNDS/UTI 15.18%
NON-INSTITUTION 10.47%
FI/BANKS/INSURANCE 1.05%
GOVERNMENT 0%
FII 0%

About Orchid Pharma Ltd.

Orchid Pharma Ltd. was incorporated in the year 1992. Its today's share price is 1062.7. Its current market capitalisation stands at Rs 5429.99 Cr. In the latest quarter, company has reported Gross Sales of Rs. 6658.98 Cr and Total Income of Rs.6853.29 Cr. The company's management includes Shubha Singh, Kapil Dayya, Manoj Kumar Goyal, Dharam Vir, Tanu Singla, Mridul Dhanuka, Manish Dhanuka, Ram Gopal Agarwal.

It is listed on the BSE with a BSE Code of 524372 , NSE with an NSE Symbol of ORCHPHARMA and ISIN of INE191A01027. It's Registered office is at Orchid Towers,313 , Valluvar Kottam High Road,NungambakkamChennai-600034, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are CNGSN & Associates LLP, Sahni Natrajan & Bahl, Singhi & Co, SNB Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.